INT30193

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 1985
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 20
Total Number 20
Disease Relevance 1.69
Pain Relevance 11.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (Ubqln1) nucleus (Ubqln1) protein complex (Ubqln1)
cytoplasm (Ubqln1)
Anatomy Link Frequency
striatum 4
DA neurons 2
neurons 2
neuronal 1
blood 1
Ubqln1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dopamine 1711 100.00 Very High Very High Very High
cerebral cortex 12 100.00 Very High Very High Very High
Hippocampus 45 99.52 Very High Very High Very High
gABA 11 99.08 Very High Very High Very High
midbrain 16 98.88 Very High Very High Very High
Ventral tegmentum 187 98.32 Very High Very High Very High
Morphine 4 97.90 Very High Very High Very High
Nucleus accumbens 92 95.88 Very High Very High Very High
cocaine 79 94.00 High High
drug abuse 8 93.40 High High
Disease Link Frequency Relevance Heat
Stress 39 100.00 Very High Very High Very High
Targeted Disruption 12 97.12 Very High Very High Very High
Urological Neuroanatomy 18 96.00 Very High Very High Very High
Hyperglycemia 8 94.80 High High
Drug Dependence 16 93.40 High High
Congenital Anomalies 8 75.36 Quite High
Affective Disorder 6 70.52 Quite High
Diabetes Mellitus 48 67.80 Quite High
Attention Deficit Hyperactivity Disorder 9 67.12 Quite High
Convulsion 51 66.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The data indicate that dopaminergic neurones surviving partial lesions of the nigrostriatal pathway synthesize and release DA at an elevated but submaximal rate.
Localization (release) of DA associated with dopamine
1) Confidence 0.12 Published 1985 Journal Neuropharmacology Section Abstract Doc Link 2858830 Disease Relevance 0 Pain Relevance 0.67
Synthesis and release of DA can be further enhanced to a large extent by drugs.
Localization (release) of DA associated with dopamine
2) Confidence 0.12 Published 1985 Journal Neuropharmacology Section Abstract Doc Link 2858830 Disease Relevance 0 Pain Relevance 0.60
Morphine (20 mg/kg, 30 min) and haloperidol (2.5 mg/kg, 60 min), i.e. drugs known to accelerate the turnover and release of DA, further elevated the DOPAC/DA and HVA/DA ratios in lesioned striata to levels approx. 5 times higher than the ratios measured on contralateral sides of saline-treated controls.
Localization (release) of DA associated with dopamine and morphine
3) Confidence 0.12 Published 1985 Journal Neuropharmacology Section Abstract Doc Link 2858830 Disease Relevance 0 Pain Relevance 0.74
Release of DA per surviving neurone was assessed by measuring the ratios of the concentrations of 3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HVA) to DA.
Localization (Release) of DA associated with dopamine
4) Confidence 0.12 Published 1985 Journal Neuropharmacology Section Abstract Doc Link 2858830 Disease Relevance 0 Pain Relevance 0.53
-aminobutyric acid; DA, dopamine; DMSO, dimethylsulfoxide; IP, intraperitoneal; IM, immobilization stress; ANOVA, analysis of variance; df, degree of freedom



Localization (immobilization) of DA associated with stress and dopamine
5) Confidence 0.03 Published 2002 Journal BMC Pharmacol Section Body Doc Link PMC137594 Disease Relevance 0.32 Pain Relevance 0.24
However, DA release induced by HPC stimulation has been shown to augment subsequent hippocampal-evoked neural activity of NAc neurons (Floresco, 2007; Floresco et al., 2001b).
Localization (release) of DA in neural associated with nucleus accumbens, dopamine and hippocampus
6) Confidence 0.02 Published 2010 Journal Behav Neurosci Section Body Doc Link PMC3002220 Disease Relevance 0 Pain Relevance 0.74
Finally, local infusion of insulin into the striatum of STZ-treated animals significantly recovers the ability of AMPH to stimulate DA release as measured by high-speed chronoamperometry.
Localization (release) of DA in striatum associated with dopamine
7) Confidence 0.02 Published 2007 Journal PLoS Biology Section Abstract Doc Link PMC2020502 Disease Relevance 0 Pain Relevance 0.21
Importantly, others have reported decreases in AMPH-induced DA release in NAc dialysates collected in freely moving rats [65].
Localization (release) of DA associated with dopamine
8) Confidence 0.02 Published 2007 Journal PLoS Biology Section Body Doc Link PMC2020502 Disease Relevance 0.17 Pain Relevance 0.21
Figure 3 shows the effect of LY294002 pretreatment on AMPH-induced DA release.
Localization (release) of DA associated with dopamine
9) Confidence 0.02 Published 2007 Journal PLoS Biology Section Body Doc Link PMC2020502 Disease Relevance 0 Pain Relevance 0.44
STZ-treated rats also had a significantly lower amount of released DA (Figure 2C).
Localization (released) of DA associated with dopamine
10) Confidence 0.02 Published 2007 Journal PLoS Biology Section Body Doc Link PMC2020502 Disease Relevance 0 Pain Relevance 0.60
Once DA is released into the synapse, the DA transporter (DAT) is the primary mechanism for clearing the transmitter from the extracellular space, particularly within the striatum [3–5].
Localization (released) of DA in striatum associated with dopamine
11) Confidence 0.02 Published 2007 Journal PLoS Biology Section Body Doc Link PMC2020502 Disease Relevance 0.29 Pain Relevance 0.40
In addition, our data show that the release of DA, determined by high-speed chronoamperometry (HSCA) in the striatum, in response to AMPH, is severely impaired in these insulin-deficient rats.
Localization (release) of DA in striatum associated with dopamine
12) Confidence 0.02 Published 2007 Journal PLoS Biology Section Abstract Doc Link PMC2020502 Disease Relevance 0 Pain Relevance 0.26
Here we show that pharmacological manipulation of the PI3K signaling pathway caused by hypoinsulinemic conditions or selective pharmacological inhibition/activation of PI3K dramatically regulates the ability of AMPH to evoke DAT-mediated DA release in the striatum, as determined by HSCA.
Localization (release) of DA in striatum associated with dopamine
13) Confidence 0.02 Published 2007 Journal PLoS Biology Section Body Doc Link PMC2020502 Disease Relevance 0.07 Pain Relevance 0.28
It is possible that factors other than PI3K signaling (e.g., altered blood glucose levels) might contribute to the blunted AMPH-induced DA release caused by STZ treatment.
Localization (release) of DA in blood associated with dopamine
14) Confidence 0.02 Published 2007 Journal PLoS Biology Section Body Doc Link PMC2020502 Disease Relevance 0 Pain Relevance 0.55
While controversial [68], it was also hypothesized that DA in the cerebral cortex may be released from noradrenergic neurons [59], since after 6-OHDA lesion of VTA, there was no change in the concentration of extracellular DA in cerebral cortex, while there was a marked decrease in the ipsilateral nucleus accumbens.
Localization (released) of DA in neurons associated with nucleus accumbens, ventral tegmentum, dopamine and cerebral cortex
15) Confidence 0.01 Published 2010 Journal CNS Neuroscience & Therapeutics Section Body Doc Link PMC2904493 Disease Relevance 0.50 Pain Relevance 1.00
Taken together, these data indicate that the increase in DA release is independent of the firing activity of VTA DA neurons, during not only subacute but also long-term administration of bupropion [28,29].
Localization (release) of DA in DA neurons associated with ventral tegmentum and dopamine
16) Confidence 0.01 Published 2010 Journal CNS Neuroscience & Therapeutics Section Body Doc Link PMC2904493 Disease Relevance 0 Pain Relevance 0.70
NE and DA neurons converge in the medial PFC where NE terminals regulate DA release in this brain region.
Localization (release) of DA in DA neurons associated with dopamine
17) Confidence 0.01 Published 2010 Journal CNS Neuroscience & Therapeutics Section Body Doc Link PMC2904493 Disease Relevance 0.22 Pain Relevance 1.11
However, in vivo studies have shown that a bupropion-induced sensitization is rather due to an increase in the ability of bupropion to release DA [125,126].
Localization (release) of DA associated with dopamine
18) Confidence 0.01 Published 2010 Journal CNS Neuroscience & Therapeutics Section Body Doc Link PMC2904493 Disease Relevance 0 Pain Relevance 0.70
In normal condition, where neurons efficiently process information, NE is released to strengthen signal detected as desirable, while in the case of neurons receiving inputs considered as noise, DA is released to weaken these inappropriate connections [77].
Localization (released) of DA in neurons associated with dopamine
19) Confidence 0.01 Published 2010 Journal CNS Neuroscience & Therapeutics Section Body Doc Link PMC2904493 Disease Relevance 0.13 Pain Relevance 0.38
It is difficult to dissociate changes in DA release from changes in DA neuronal activity.
Localization (release) of DA in neuronal associated with dopamine
20) Confidence 0.01 Published 2010 Journal CNS Neuroscience & Therapeutics Section Body Doc Link PMC2904493 Disease Relevance 0 Pain Relevance 0.72

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox